The potential for selective pharmacological therapies through biased receptor signaling
- PMID: 22947056
- PMCID: PMC3506267
- DOI: 10.1186/2050-6511-13-3
The potential for selective pharmacological therapies through biased receptor signaling
Abstract
The discovery that not all agonists uniformly activate cellular signaling pathways (biased signaling) has greatly changed the drug discovery process for agonists and the strategy for treatment of disease with agonists. Technological advances have enabled complex receptor behaviors to be viewed independently and through these assays, the bias for an agonist can be quantified. It is predicted that therapeutic phenotypes will be linked, through translational studies, to quantified scales of bias to guide medicinal chemists in the drug discovery process.
Figures



References
-
- Mailman RB, Lawler CP, Lewis MM, Blake B. In: Dopamine Receptor Subtypes: From Basic Science to Clinical Application. Jenner P, Demirdamar R, editor. IOS Press, New York; 1998. Functional effects of novel dopamine ligands: Dihydrexidine and Parkinson’s disease as a first step; pp. 53–65.
-
- Roerig SC, Loh HH, Law PY. Identification of three separate guanine nucleotide- binding proteins that interact with the δ-opioid receptor in NG108-15 X glioma hybrid cells. Mol. 1992;41:822.831. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources